Form 4: Hyperfine Director Dan Wolterman Receives Stock Options

Director Dan Wolterman was granted 157,700 stock options in Hyperfine, Inc. as part of his compensation package.

Summary

• Director Dan Wolterman received a grant of 157,700 stock options on May 22, 2026.
• The options have an exercise price of $1.49 per share.
• The options are set to expire on May 22, 2036.
• The grant is subject to vesting on the date of the next regular annual stockholders meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The options vest on the date of the Issuer's next regular annual stockholders meeting, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure alignment with company performance and shareholder interests.

Comparison to Industry Standards

• The use of time-based vesting tied to annual meetings is a standard practice for board compensation in the medical technology sector.
• The grant size is consistent with typical equity compensation packages for directors of small-cap healthcare companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon exercise of options.

Next Steps

• Vesting of options at the next regular annual stockholders meeting.

Key Dates

Keywords

Hyperfine, HYPR, Director Compensation, Stock Options, SEC Form 4, Insider Transaction